Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.

Abstract excerpt

Direct-acting antiviral drugs (DAA) are safe and effective in the HCV population. However, in patients with decompensated cirrhosis and/or active hepatocellular carcinoma or relapse to NS5A inhibitors, response rates are lower and DAA therapy must be postponed until after liver transplant in an era of organ shortage and suboptimal donors. We aimed to assess the prevalence of patients still HCV infected at time of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminoisobutyric Acids
• Share to Cyclopropanes